Synlogic Inc. (SYBX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for SYBX, including 1 leadership change and 1 SEC filing. The most recent was published Nov 2, 2026.
Price$0.58+0.00 (+0.00%)
2026-08-032026-11-03
News · 26 weeks8+100%
2026-05-102026-11-01
Mix390d
- SEC Filings2(67%)
- Leadership1(33%)
Latest news
25 items- SECSEC Form 425 filed by Synlogic Inc.425 - SYNLOGIC, INC. (0001527599) (Subject)
- PRCaldera Therapeutics Appoints Michelle Doig as Chief Financial Officer and Lee Giguere as Chief Legal OfficerAppointments strengthen executive leadership team as Caldera prepares for its transition to a publicly traded company and advances CLD-423 into Phase 2 IBD trials Caldera Therapeutics, Inc. ("Caldera"), a privately held clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting IL-23p19 and TL1A for the treatment of inflammatory bowel disease (IBD) and other immune-mediated diseases, today announced the appointments of Michelle Doig as Chief Financial Officer and Lee Giguere, J.D., as Chief Legal Officer. "We are pleased to welcome Michelle and Lee to Caldera at this important stage in our company’s evolution," said Praveen Tipirneni, MD, MBA, Chief Executi
- SECSEC Form 10-Q filed by Synlogic Inc.10-Q - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form 425 filed by Synlogic Inc.425 - SYNLOGIC, INC. (0001527599) (Subject)
- SECSynlogic Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - SYNLOGIC, INC. (0001527599) (Filer)
- PRSynlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private PlacementCombined company to operate as Caldera Therapeutics, developing CLD-423, a potential first-in-class TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease and other immune-mediated diseases Concurrent upsized $278 million private placement committed by a syndicate of leading healthcare institutional investors and mutual funds expected to fund operations through Phase 2 clinical trials in ulcerative colitis and Crohn’s disease, with cash runway projected into 2029 Synlogic, Inc. (OTC:SYBX) ("Synlogic") and Caldera Therapeutics, Inc. ("Caldera"), a privately held clinical-stage biotechnology company developing CLD-423, a potential first-in-class TL1A x IL-23p19 bispecific anti
- SECSEC Form 25-NSE filed by Synlogic Inc.25-NSE - SYNLOGIC, INC. (0001527599) (Subject)
- SECSEC Form 10-Q filed by Synlogic Inc.10-Q - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Synlogic Inc.10-K/A - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form 10-K filed by Synlogic Inc.10-K - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: Synlogic Inc. filed SEC Form 8-K: Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K/A - SYNLOGIC, INC. (0001527599) (Filer)
- SECSynlogic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - SYNLOGIC, INC. (0001527599) (Filer)
- SECSynlogic Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - SYNLOGIC, INC. (0001527599) (Filer)
- SECSynlogic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form 10-Q filed by Synlogic Inc.10-Q - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Synlogic Inc.SCHEDULE 13G/A - SYNLOGIC, INC. (0001527599) (Subject)
- SECSEC Form DEF 14A filed by Synlogic Inc.DEF 14A - SYNLOGIC, INC. (0001527599) (Filer)
- INSIDEROfficer Dooley Mary Beth sold $284 worth of shares (157 units at $1.81), decreasing direct ownership by 1% to 12,744 units (SEC Form 4)4 - SYNLOGIC, INC. (0001527599) (Issuer)
- SECSEC Form EFFECT filed by Synlogic Inc.EFFECT - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: SEC Form S-3/A filed by Synlogic Inc.S-3/A - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form S-3 filed by Synlogic Inc.S-3 - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form 10-Q filed by Synlogic Inc.10-Q - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form 10-Q filed by Synlogic Inc.10-Q - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Synlogic Inc.10-K/A - SYNLOGIC, INC. (0001527599) (Filer)
- INSIDERDirector Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)4 - SYNLOGIC, INC. (0001527599) (Issuer)
SYBX FAQ
8 questionsWhat does Synlogic Inc. do?
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that...What is the latest news on SYBX?
In the last 30 days Quantisnow tracked 2 wire items for SYBX: 1 leadership change and 1 SEC filing. The most recent was published on November 2, 2026.Where does SYBX stock trade?
Synlogic Inc. (SYBX) is listed on NASDAQ.What sector and industry is SYBX in?
Synlogic Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Synlogic Inc. go public?
Synlogic Inc. (SYBX) completed its IPO in 2015.What are analysts saying about SYBX?
Across the last 6 analyst actions on Synlogic Inc., there were 2 upgrades and 0 downgrades. The most recent action was from Oppenheimer: Outperform with a $7.00 price target on 2021-11-24. Recent price targets range from $7.00 to $11.00.What companies are similar to SYBX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SYBX side-by-side with any of them on Quantisnow.How can I track SYBX on Quantisnow?
Quantisnow aggregates Synlogic Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SYBX to receive live email and push alerts on every new disclosure.